Clinical TrialAug 12, 2026, 08:31 AM
Propanc Biopharma Advances Cancer Drug PRP to Phase 1b Clinical Study
AI Summary
Propanc Biopharma provided a scientific comparison of its lead candidate PRP with RAS-targeted approaches, highlighting PRP's unique mechanism for treating aggressive, treatment-resistant cancers like PDAC. The company plans to file a clinical trial application in Q4 for a Phase 1b study in advanced cancer patients, aiming to demonstrate PRP's potential as a long-term treatment option. PRP, which has FDA Orphan Drug Designation for pancreatic cancer, works by promoting cancer cell differentiation and reversing EMT, offering a non-cytotoxic approach.
Key Highlights
- Propanc's lead candidate PRP advances to Phase 1b clinical study.
- Clinical trial application for Phase 1b study expected in Q4 this year.
- PRP targets aggressive, treatment-resistant cancers like PDAC.
- Preclinical data showed >90% mean tumor growth inhibition in PDAC models.
- PRP extended median overall survival >2.5-fold versus controls (p < 0.001).
- PRP holds FDA Orphan Drug Designation for pancreatic cancer.
- Phase 1b study will enroll 40-45 patients with advanced solid tumors.
Price Impact
More from PPCB